Randomized double-blind trial of oral essential amino acids association is evident not only for patients with subnorfor dialysis-associated hypoalbuminemia.
have reported the beneficial effects of amino acid suppleMethods. Subjects with a mean three-month prestudy serum albumin of 3.8 g/dL or less and who demonstrated Ն90% comments on a wide range of outcome measures. The interpliance during a two-week run-in period were randomized to pretation of these results is limited, however, as only a 3.6 g of essential amino acids (EAAs) or placebo three times minority of these studies were randomized [6] [7] [8] , and in daily with meals for three months. Randomization was stratiaddition, none were double blind. We have previously fied by dialysis modality and by severity of the hypoalbuminemia. The primary study outcome was change in the average reported the beneficial effects of essential amino acid of three monthly serum albumin measurements between base-(EAA) supplements to a very low-protein diet in preline and follow-up.
venting hypoalbuminemia at the onset of dialysis [9] and Results. Fifty-two patients were randomized; 47 patients (29 in improving survival on subsequent dialysis [10] . We hemodialysis and 18 peritoneal dialysis) met the predetermined primary analysis criteria. The mean compliance rates averaged therefore carried out the following investigator-initiated, 75 , 70, and 50% at months 1, 2, and 3, respectively, and were industry-supported, randomized, double-blind, placebosimilar for EAAs and placebo. Serum albumin in the hemodialcontrolled study in order to examine whether oral EAA ysis patients, EAA versus placebo, improved [(mean Ϯ SE) supplements could improve serum albumin levels in 0.22 Ϯ 0.09 g/dL, P ϭ 0.02]. Changes in peritoneal dialysis patients were not significant (0.01 Ϯ 0.15 g/dL), but approached maintenance dialysis patients with hypoalbuminemia.
significance for the total study group (0.14 Ϯ 0.08 g/dL, P ϭ 0.08). Patients in the very low albumin strata (Ͻ3.5 g/dL) improved more than those in the low albumin strata (3.5 to 3.8
METHODS
g/dL, P Ͻ 0.01). There was a significant correlation (r ϭ 0.83, The study participants were selected from two urban, P ϭ 0.001) within the hemodialysis EAA group between the baseline C-reactive protein level and improvement in serum hospital-affiliated, dialysis units in Baltimore, Maryland, albumin. Improvements were also seen in grip strength and USA. For inclusion, subjects were required to be 18 years SF-12 mental health score, but not in serum amino acid levels, or older, not to have taken any investigational drug in SF-12 physical health score, or anthropometric measurements.
Conclusions. Oral EAAs induce a significant improvement the month prior to study entry, and to have a mean (Ϫ90, in the serum albumin concentration in hemodialysis but not Ϫ60, Ϫ30-day prerandomization) serum albumin of 3.8
peritoneal dialysis subjects. Further study of their long-term g/dL or less. Patients who, in the opinion of their primary effects on morbidity and mortality is warranted.
nephrologist, were poorly compliant with medications or who were estimated to have a life expectancy of less than three months were excluded. The study protocol Hypoalbuminemia is a powerful predictor of poor outwas reviewed by the institutional review boards of both come for patients on maintenance dialysis [1] [2] [3] [4] [5] . This participating centers. All patients gave informed written consent, which was obtained by a researcher other than as for the actual study. At the end of the run-in period, At study entry and monthly thereafter, study subjects compliance was assessed by weighing the pill container.
had anthropometric measurements, grip strength, and The container held additional tablets over that necessary quality-of-life assessments performed. They were addifor two weeks of full compliance. Patients who demontionally questioned regarding the development of any strated less than 90% compliance were excluded.
adverse events or hospitalizations. Anthropometric mea-A computer-derived, stratified randomization scheme surements consisted of triceps skin fold thickness and was prepared by the study sponsors prior to the start midarm muscle circumference and were measured using of the study. Study investigators were blinded to the a standard protocol [12] . Midarm muscle area (MAMA) randomization scheme and to the randomization block was calculated from this formula: size. Patients were stratified prerandomization by dial-MAMA ϭ midarm circumference ysis modality (hemodialysis or peritoneal dialysis) and by albumin level (very low serum albumin, Ͻ3.5 g/dL, Ϫ (3.14 · triceps skin fold thickness) [13] or low serum albumin, 3.5 to 3.8 g/dL). Patients were Anthropometric measurements were made after dialrandomized to take five Aminess N tablets or placebo ysis and were performed on the right side, unless a functhree times a day with meals for three months. The study tioning access was present there. Grip strength measuretablet contained 720 mg of amino acids, including nine ments were performed on the dominant hand using a l-EAAs (histidine 45 mg, isoleucine 60 mg, leucine 90 mg, Jamar hydraulic dynamometer (Sammons Preston, Bollysine 65 mg, methionine 90 mg, phenylalanine 70 mg, threonine 65 mg, tryptophan 25 mg, valine 135 mg) and ingbrook, IL, USA). The Short Form 12 (SF12) instru-75 mg of l-tyrosine. This preparation was based on a ment was used to assess quality of life. Results were modification of the recommended daily intake suggested analyzed as outlined by Ware, Kosinski, and Kelly [14] , by Rose, as outlined by Alvestrand et al [11] . It is formuwith the calculation of a summary mental and physical lated specifically to address the disturbances in amino health score. Values were standardized to the U.S. popuacid metabolism seen in uremia. The placebo tablets lation, in which the population mean is 50 and the stanused in our study were identical in appearance to the dard deviation is 10 [14] . EAA tablets. To help improve the quality of the mask, A 24-hour dietary history was taken from patients at especially on first opening the pill container, a small the beginning and end of the study by an experienced quantity of methionine was added to the canister of dryrenal dietitian. The patient's 24-hour energy and total ing agent in the placebo containers. Tablets were disprotein intake was calculated using the "Nutritionist 4" pensed monthly. As with the run-in period, the returned software package (N Squared Computing, Salem, OR, pill containers, with the unused pills, were weighed to USA). The dietary assessment excluded the study mediassess compliance. During the course of the study, subcation. Urea kinetic studies were performed monthly for jects were blinded to their serum albumin results. No hemodialysis patients, using a two-blood urea nitrogen new dietary supplements were prescribed, and no other (BUN) sample and a variable-volume, single-pool urea amino acid preparations were used. The patients' dialysis kinetic model [15] , and quarterly for peritoneal dialysis and routine medical care continued to be supervised by patients using total Kt/V measured using a standardized the patients' primary nephrologist without the involvemethod [16] . Routine dialysis laboratory tests (basic ment of the study investigators.
chemistry, metabolic panel, and full blood count) were also monitored.
Outcome measures
At randomization (day 0) and at days 30, 60, and Laboratory assays 90, postrandomization serum albumin, transferrin, and Blood tests from the two clinics were analyzed in their prealbumin levels were measured. To explore possible usual laboratories. Thus, each patient had all of his/her mechanisms leading to an improvement in serum albublood tests analyzed in the same laboratory. Albumin min levels, an additional serum sample was obtained and was assayed using the bromocresol green method for frozen at Ϫ70ЊC. All laboratory tests were nonfasting which the coefficient of variation in both laboratories and in the hemodialysis patients were performed prior during the study period was under 2.5%. Prealbumin, to commencing dialysis. The primary study outcome transferrin, and C-reactive protein (CRP) levels were measure was the difference between the follow-up mean measured by nephelometry. Serum amino acid levels (30-, 60-, and 90-days postrandomization) serum albumin were analyzed using ion exchange chromatography with and the baseline mean (Ϫ60, Ϫ30, 0-day prerandomizaa Beckman analyzer, model 6300. Serum free tryptophan tion) serum albumin level. When one of the follow-up was measured as previously described [17] . Free indoxyl blood tests was missing, the available results were used. sulfate was measured by the same high-performance liqBlood tests measured during hospitalizations were not used.
uid chromatographic (HPLC) method. Serum nitrates and nitrites were measured as described by Everett et the required follow-up outpatient serum albumin measurements, as they became ill within the first month of the al, and their sum was calculated [18] . study and underwent prolonged hospitalizations, which Statistical analysis eventually proved fatal. The study population was broadly representative of Data were independently double entered and electronically compared. The internal consistency of the data our inner-city dialysis population, with a predominance of black subjects. The mean age of the study group was was assessed using time trend analysis and by examining outliers. The analysis plan was outlined in the original 65 years, and the mean duration of dialysis was 3.4 years. Twenty-six patients were affiliated with the Good Samarstudy protocol and prepared in detail prior to release of the randomization code. Normality was assessed using itan Hospital (19 treated with hemodialysis and 7 with peritoneal dialysis) and 21 with the Johns Hopkins Hosthe Shapiro-Wilks test and with quartile-quartile plots [19] . The primary analysis was an intention-to-treat analpital (10 treated with hemodialysis and 11 with peritoneal dialysis). The etiology of the renal failure was diabetes ysis of subjects who were alive, on dialysis, and had at least one serum albumin level measured at 45 or more mellitus in 38%, hypertension in 38%, glomerulonephritis in 19%, and miscellaneous causes in 4% of subjects. days after randomization. Our primary analysis was an analysis of variance, with change in mean serum albumin Among the hemodialysis patients, 41% were dialyzed with a cellulose triacetate membrane, 31% with an AN69 as the dependent variable adjusted for dialysis center, dialysis modality, and albumin strata. We a priori hymembrane, 14% with a polysulfone membrane, and 14% with a cellulose acetate membrane. Only the cellulose pothesized the possibility of interaction between the change in serum albumin and dialysis modality and/or triacetate membrane was reused, with a mean of 20 reuses. An arteriovenous access (either a graft or a fistula) the degree of hypoalbuminemia at baseline.
Estimates of the magnitude of change in mean serum was the predominant form of angioaccess used in the hemodialysis group, with an average blood flow of 450 albumin were obtained using least-squares linear regression. Routine diagnostic testing of the model included mL/min, an average treatment duration of four hours and bicarbonate-based dialysate. Fifty-five percent of the examination of the distribution of residual values and investigation of points with high leverage and/or influperitoneal dialysis subjects were treated with continuous cycler peritoneal dialysis and 45% with traditional conence [19] . In addition, the analysis was repeated using the Huber-White robust variance estimator [20] . Other tinuous ambulatory peritoneal dialysis; all patients used standard glucose-based dialysate. There were no signifistudy variables were examined using independent sample t-test, Mann-Whitney U-test, or chi-square test as cant differences in the underlying cause of renal failure, type of hemodialysis membrane used, or peritoneal dialappropriate. The correlation between CRP levels and albumin levels was examined using the nonparametric ysis modality between the EAA and the placebo groups. The stratified randomization scheme resulted in an Spearman rank correlation coefficient. Analyses were performed using SPSS Base 7.5 (SPSS Inc., Chicago, IL, equal allocation of Aminess N and placebo. Twentynine hemodialysis patients (15 in the very low albumin USA) and Stata release 5 (StataCorp, College Station, TX, USA). strata and 14 in the low albumin strata) and 18 peritoneal dialysis patients (14 in the very low and 4 in the low albumin strata) were randomized. The baseline demo-RESULTS graphic and laboratory results are shown in Tables 1 and 2 .
Baseline data
The study included nine patients with a body mass index of greater than 30; seven of these subjects were hemodialOf the two clinics combined, approximately 174 out of a total of 393 patients met the study's entry criteria.
ysis patients, of whom six were randomized to EAA treatment. As a result, the median (intraquartile range) Seventy-nine of these patients entered the study run-in phase, of which 52 patients (31 hemodialysis and 21 peribody mass index for the hemodialysis active group was 30.6 Ϯ 13.5 kg/m 2 , while that for the placebo group was toneal dialysis) were subsequently randomized. However, five of these patients (4 active and 1 placebo) failed to 24.6 Ϯ 4.2 kg/m 2 (P ϭ 0.05). Skin fold thickness and MAMA varied with body mass index, and therefore, meet the prespecified protocol requirements for inclusion in the primary analysis. The ineligibility of these these parameters were also significantly larger in the hemodialysis active as compared with the placebo group. patients was established in accordance with the study protocol and before the release of the randomization Mean values of skin fold thickness and MAMA for hemodialysis EAA versus placebo subjects were 18.0 versus code. Three of these patients had no follow-up albumin at 45 or more days postrandomization because of transfer 12.4 mm (P ϭ 0.02) and 29.8 versus 25.7 cm (P ϭ 0.05), respectively. At baseline, there was no significant differto another dialysis unit (1 subject), receipt of a cadaveric renal allograft (1 subject), and patient death (1 subject).
ence in grip strength between the EAA (mean grip strength 20.7 kg force) and the placebo group (mean The two remaining patients (1 active and 1 placebo) lacked grip strength 23 kg force). In the peritoneal dialysis with a mean difference (95% CI) between EAA and placebo of 0.01 (Ϫ0.31, 0.34) g/dL. The effect of treatgroup, there was no significant difference for any of these baseline parameters. ment on the total study group (both modalities combined) reflects the larger representation of hemodialysis Compliance subjects and approached but did not reach significance, with an adjusted mean serum albumin change (95% CI) Compliance, measured as a percentage of the prescribed number of pills absent from the returned pill of 0.14 (Ϫ0.02, 0.30) g/dL higher in the EAA than in the placebo arm (P ϭ 0.08). A nonparametric analysis containers, averaged 75, 70, and 50% during the first, second, and third months of the trial. Compliance rates using a robust variance estimator yielded similar results (data not shown). In a secondary analysis, the significant were almost identical for the Aminess N group and placebo, but were approximately 10% lower for peritotreatment effect for hemodialysis patients persisted (P ϭ 0.04) after adjustment for baseline body weight. The neal dialysis than for hemodialysis patients (Fig. 1) .
mean serum albumin values at each time point are shown Change in serum albumin in Figure 3 . The mean Ϯ SD improvement in serum albumin for The primary analysis revealed a significant qualitative interaction (P ϭ 0.02) between the effects of treatment the total study population, in EAA versus placebo subjects, was 0.21 Ϯ 0.12 g/dL for subjects in the very low allocation and dialysis modality (Fig. 2) . For the hemodialysis group, the change in mean serum albumin (95% albumin strata, as compared with 0.05 Ϯ 0.10 g/dL for those in the low albumin strata, interaction P Ͻ 0.01. A CI) from baseline to follow-up, adjusted for center and albumin strata, was 0.22 (0.03, 0.40) g/dL higher in the similar result was present for hemodialysis patients: very low stratum (mean Ϯ SD), change in serum albumin, EAA than the placebo group (P ϭ 0.02). The peritoneal dialysis group failed to demonstrate any improvement 0.31 Ϯ 0.17 g/dL, low albumin stratum (mean Ϯ SD) change, 0.14 Ϯ 0.1 g/dL, interaction P ϭ 0.05. Our ability Secondary outcomes to examine this effect in peritoneal dialysis patients was There was no significant change over the study period limited by the relatively small numbers of subjects in this in either serum transferrin or prealbumin levels nor in group (4 subjects in the peritoneal dialysis low albumin the potential confounding laboratory or dietary recall stratum). Nevertheless, a similar trend for an increased variables (Table 3) . The other routinely measured labodegree of improvement in the very low albumin stratum ratory parameters similarly showed no significant difference with treatment (data not shown). There was a borwas also seen in the peritoneal dialysis group. derline significant improvement in grip strength in the (intraquartile range) change in actual body weight between baseline and follow-up was 0 (1.0) kg. hemodialysis group, with a mean (95% CI) change, EAA vs. placebo, of 2.27 (0.0, 5.5) kg force. There was no
The mean SF12 mental health score at randomization was similar for both dialysis modalities and averaged 52. significant change in the other anthropometric measurements in the hemodialysis group. The only significant
The mean (95% CI) difference in change in mental health score between EAA and placebo participants for change among these parameters in the peritoneal dialysis group was a decrease of 2.55 mm in the median skin fold all study subjects was 5.0 (0.8 to 9.2, P ϭ 0.02). The mean (95% CI) difference for change in hemodialysis thickness of the EAA versus placebo subjects (P ϭ 0.04). Among the nine obese subjects in the study, the mean patients was 5.5 (CI, Ϫ0.4 to 11.4, P ϭ 0.07) and for was excluded from the primary analysis, as discussed previously. The second was hospitalized seven weeks after study entry and made an uneventful recovery. An additional 12 adverse events, which did not require hosperitoneal dialysis was 3.8 (Ϫ2.2, 9.8, P Ͼ 0.1; Table 3) .
pitalization, occurred, five in the EAA group and seven The mean physical health score at baseline was 36. There in the placebo group. As expected, the combined hospiwas no significant difference in physical well being betalization/adverse event rate was higher in the very lowtween the EAA and the placebo arms, at either baseline albumin strata (22 of 32 total advents) as compared with or at follow-up. the low-albumin strata. Three patients died within three months of randomization; two were on active treatment, Aminograms and one was on placebo. The reported causes of death Serum aminograms were measured at both randomwere trauma, myocardial infarction, and septicemia, reization and follow-up for the 14 hemodialysis patients spectively. In no case was there any evidence of a contriwho received Aminess N treatment. Baseline aminobution of study involvement to the development of any grams revealed high levels of the measured serum amino adverse event, hospitalization, or death. acids except valine, tyrosine, glutamine, cystine, and amino-N-butyric acid. There was no significant change DISCUSSION in the ratio of essential to non-EAA during the study (Table 4) . Serum valine levels increased, although not Hypoalbuminemia is a powerful predictor of poor outcome in patients on maintenance dialysis. In a large significantly, from a mean baseline level of 165 to 205 retrospective study, Lowrie and Lew demonstrated a requirements results in the further diversion of consumed protein from anabolic to catabolic pathways. Thus, dialtwofold increased risk of dying for patients with a serum albumin of between 3.5 and 4.0 g/dL as compared with ysis-associated anorexia underlies the inability of many dialysis patients to increase their oral intake voluntarily, a reference group with albumin levels of 4.0 to 4.5 g/dL [1] . Several other large studies have supported these despite intensive instruction and supervision by renal dietitians. The use of amino acid supplements, by either results in both hemodialysis [3, 4, 21] and peritoneal dialysis [2, 5] . Hypoalbuminemia is not only a powerful the enteral or parenteral route, may help overcome this shortfall, while avoiding the provision of additional toxpredictor of outcome. It also is highly prevalent among dialysis patients. The Health Care Financing Administrains, such as excess potassium or phosphate. Several studies, most of them from the late 1970s and tion's core indicators project conducted in 1997 found, using the bromocresol green method, that 43% of peritoearly 1980s, have examined the effect of oral EAA on serum amino acid levels of hemodialysis patients [8, [36] [37] [38] [39] [40] [41] . neal dialysis and 16.5% of hemodialysis patients had serum albumin levels below 3.5 g/dL [22] .
Interpretation of these results is complicated by the different amino acids formulations used and by the omission The etiology of hypoalbuminemia in dialysis patients is both complex and multifactorial. It is contributed to of relevant clinical information, particularly regarding the achieved dialysis dose and the degree of acid-base by uncontrolled acidosis [23] [24] [25] , by protein losses in the dialysate [26, 27] , and at least in some cases, by a chronic control. In the majority of these studies, subnormal serum concentrations of EAAs were improved by the adinflammatory state [28] [29] [30] . This combination of factors contributes to the increased protein requirement needed ministered supplement [8, 36, 38, 40, 41] . In addition, Philips, Havard, and Howard, in a nonrandomized though to maintain a neutral nitrogen balance in these patients [31, 32] . At the same time, dialysis is associated in many controlled study, reported a mean increase in serum albumin levels of 0.2 g/dL (P ϭ 0.02) [36] . An advantage patients with moderately severe anorexia. This anorexia possibly results from the combination of inadequate dialof the enteral, as compared with the parenteral, route of supplementation is that it is relatively inexpensive. ysis, the ingestion of multiple medications, the presence of comorbid problems such as diabetic gastroparesis, The Aminess N supplement, at the dose prescribed in our study, costs approximately $5 a day or $450 for the as well as more general psychosocial problems, such as poverty and depression [33] . The result is that dialysis total three-month course of treatment. Intradialytic parenteral nutrition (IDPN) was widely patients frequently have an inadequate oral intake of both total protein and energy. Moreover, even though used in the United States in the past. It had the advantage of convenience, bypassing the need for active patient energy requirements in dialysis patients remains normal [34, 35] , the frequent failure of patients to meet these compliance. The popularity of IDPN appears to have rested more on this convenience than on the oral route acid supplements in peritoneal dialysis was markedly attenuated. As can be seen by the wide confidence interof administration, having been convincingly shown to be ineffectual. Approximately 28 studies have examined the vals for the mean difference in serum albumin between the peritoneal dialysis EAA and placebo (Ϫ0.31, 0.34), effects of IDPN in dialysis patients [reviewed in 42] , only three of which were randomized. Blondin and Ryan, in we can neither confirm nor dismiss the possibility of a beneficial effect of oral supplements in this group. an additional recent report describing the application of a standardized nutritional assessment and intervention While compliance rates deteriorated considerably during the course of the study, compliance was similar for program, reported an improvement in serum albumin of 0.2 g/dL with six months of IDPN therapy, at an estithe EAA and placebo groups, suggesting that this suboptimal compliance was not a consequence of treatment mated cost of $20,000 per patient [43] . There was an associated decrease in the mean Ϯ SD number of hospiwith amino acids per se. We instead believe that the progressive deterioration in compliance over the course talizations from 2.7 Ϯ 1.7 to 1.9 Ϯ 2.0 and of duration of hospitalizations from 20.2 Ϯ 18.9 days to 12 Ϯ 12.6 of the study resulted primarily from the large number of pills the patients were requested to take, and that days in the IDPN-treated patients. The inherent limitations of such observational studies, the great cost of IDPN, the study was placebo-controlled but lacked any formal incentives to help maintain subject compliance. The and its extremely restricted reimbursement potential have all greatly limited the current use of this approach.
mean study compliance of 9 to 10 tablets per day may form the basis of a more realistic dosing strategy in future There have been fewer published studies examining the use of amino acid-based dialysate in peritoneal dialstudies.
We were unable to demonstrate a significant improveysis patients. A study by Kopple et al using a 1.1% amino acid-based dialysate showed a net improvement in nitroment in our secondary outcomes, with the exception of improvements in grip strength and the mental health gen balance [44] . A prospective study of 15 patients showed a significant improvement in serum albumin levels (mean score. We had limited power to detect a change in either serum transferrin or prealbumin levels due to the wide change 0.24 g/dL) [45] , while a randomized trial of 105 subjects showed a significant improvement at one month variance of these measurements in comparison with the level of improvement expected with this limited course but not at two or three months of follow-up [46] .
Our study is the first clinical trial, of which we are aware, of treatment. In addition, serum transferrin levels may have been influenced by intravenous iron therapy. The to examine the potential benefits of oral amino acid supplements in hypoalbuminemic dialysis patients in a reproducibility of the standard anthropometric measurements may vary considerably, even with the use of stanrigorous fashion, using a prospective, randomized, placebo-controlled, double-blind methodology. We chose to dardized measurement techniques [13] . Furthermore, these anthropometric parameters may only slowly reexamine albumin as our primary outcome variable since its measurement is objective, and it has a proven associaspond to patients' altered nutritional status. The lack of change in the physical health score may similarly reflect tion with patient outcomes in a wide range of studies for both peritoneal and hemodialysis patients. The serum the limited follow-up period of the study and the lack of any formal associated physical rehabilitation program. albumin levels in our two participating centers were measured in different laboratories. However, both laboraThe observed borderline improvements in grip strength are in keeping with the recent report by De Bisschop et tories used the same methodology for measuring albumin levels, and our primary outcome was the within-individal of improved muscle metabolism, as measured by P 31 spectroscopy, following amino acid supplementation [47] . ual change in serum albumin, which therefore could not be influenced by any systemic bias between the two laboIn contrast to previous published studies, we did not find subnormal amino acid levels in our hemodialysis ratories. In addition, our primary analysis was adjusted for study center to control for any nonrandom differsubjects at baseline. This may partly be the result of better acid-base control and the relatively high achieved ences between the two study centers and their associated laboratories.
dialysis dose as compared with historical studies, or be influenced in part by the fact that our samples were taken It is possible that some peritoneal dialysis patients may have lost a substantial proportion of the ingested from nonfasting subjects. Similarly, while alterations in the concentrations of free tryptophan [17] , free indoxyl supplement into their dialysate. We did not measure peritoneal dialysate amino acid concentrations and so were sulfate [48] and nitrate plus nitrite [49] have been associated with chronic renal failure and dialysis, and we did unable to investigate this possibility in our study.
As a result of the smaller number of peritoneal dialysis not find any correlation between changes in these substances and change in the serum albumin. patients enrolled in the study, their lower compliance rates and the greater variance in their serum albumin Several patients in our study had a body mass index of greater than 30 but were nonetheless hypoalbuminemic. levels, as compared with the hemodialysis patients, our study's power to determine a significant effect of amino Random assignment resulted in these patients being over-represented in the Aminess N-treated hemodialysis cepted but has not been proven. In this connection, it is interesting to note that no change in serum albumin group. There is, however, a considerable prevalence of obesity in the dialysis population. In a recent study by concentration was observed by Blumenkrantz et al in severely hypoalbuminemic peritoneal dialysis patients Fleischmann et al, 24.4% of 1346 patients studied had a body mass index of 30 or greater [50] . Although obesity fed either 0.98 or 1.44 g/kg of protein for two to four weeks, despite a pronounced improvement in nitrogen has been shown to be protective when compared with a low body mass index in dialysis patients [3, 50] , the balance on the latter diet [31] .
In summary, we demonstrate a modest though signifiprognostic significance of hypoalbuminemia in this obese subgroup of individuals is not well established. While it cant improvement in serum albumin levels among hemodialysis patients treated with oral EAAs. The mean inis possible that some of the hypoalbuminemia seen in this group may have been dilutional in origin, caused by crease (0.2 g/dL) is of the same order as has been described with several other interventional studies using either intrathe difficulty in establishing accurate dry weight in obese patients, when we adjusted our primary analysis for the venous or intraperitoneal supplements. Treatment with oral supplements, such as Aminess N, however, costs patient's body mass index, the study results were unchanged. Similarly, median actual body weight was unonly a fraction of the cost of these parenteral supplements. While the observed improvements in serum albuchanged among the obese subjects over the course of the study. Both of these observations argue against the min are small, they are potentially of major clinical significance, especially as the improvement was greatest for possibility of a reduction in the patient's target dry weight, with a resultant reduced dilutional effect, as leading to patients in the very low serum albumin strata, patients who are at the greatest risk of developing complications. the observed improvement in their serum albumin levels.
The presence of elevated CRP levels among the obese We believe that oral amino acid supplements may provide both a cost-effective and safe method for improving study patients supports a role for chronic inflammation as contributing to their hypoalbuminemia, while the imthe nutritional intake of those hemodialysis patients who are unable to meet their daily protein requirements deprovement in serum albumin levels seen with treatment suggests that amino acid supplements may at least partly spite maximal conservative measures. However, before such a treatment strategy can be advocated, the potential ameliorate the nutritional consequences of chronic inflammation in these patients. The absence of any correlabenefits of oral supplements on patients' long-term outcome should be objectively assessed in a randomized, tion between change in serum albumin and change in CRP over the course of the study argues against a dedouble-blind, placebo-controlled clinical trial. crease in chronic inflammation as leading to the improvement in serum albumin. ACKNOWLEDGMENTS The current study lacked both the number of subjects
